Jacob Hanna
Hanna’s supported longevity footprint is thin: stem-cell scientist, coauthor on a 2025 aging-biology workshop paper. That links him to the field, not to a proven life-extension program.
Role
scientisthigh confidence
The evidence shows actual peer-reviewed authorship and a research program on stem-cell-derived embryo models aimed at regenerative medicine, which is the clearest channel through which he moved longevity-adjacent science forward. Delete the papers and underlying research, and most of his longevity relevance collapses.
The N6-Methyladenosine mRNA Methylase METTL3 Controls Cardia ↗Innovations in aging biology: highlights from the ARDD emerg ↗Altered ECM deposition and cell adhesion signaling in a huma ↗
also: entrepreneur
Dimension breakdown
This score rates longevity commitment only. The role tags above — scientist, investor, and the rest — say what this person is; we don't score those separately.
Evidence is still sparse for this hero. Scores are shown with low-confidence warnings until more source material is harvested.
Future vision
0.0/ 10
No provided evidence shows Jacob Hanna articulating a concrete public vision for ending aging, reversing biological decline, or materially extending healthy lifespan. The available evidence is limited to a general personal X bio and academic/citation records without future-oriented longevity claims.
low confidence
Scientific impact
3.0/ 10
Scientific impact applies because Jacob Hanna is evidenced as a stem cell scientist and coauthor on a peer-reviewed biomedical paper. However, the main citation_metrics block appears mismatched to Shanthi Johnson rather than Jacob Hanna, so it cannot anchor a high score. The usable evidence shows participation in at least one relevant, mechanistic academic study, but not field-defining citation influence for this hero.
low confidence
Capital deployed
N/A
The evidence provided contains no disclosed investments, donations, fund allocations, or institution-building capital directed toward longevity by Jacob Hanna. This dimension appears inapplicable based on the supplied record.
No evidence of capital deployment activity; available evidence portrays him as a scientist rather than a funder, donor, investor, or institution-builder.
medium confidence
Strategic taste
1.0/ 10
The dimension is applicable because Hanna appears to be a longevity-relevant scientist, but the provided evidence does not show thesis-coherent strategic bets, early contrarian choices, institution-building, capital allocation, or counterfactually important decisions. The only supported strategic signal is a broad focus on stem cell science, which is relevant but too thin to establish strategic taste.
low confidence
Field creation
0.0/ 10
The provided evidence contains no credible indication that Jacob Hanna created organizations, programs, categories, communities, protocols, or funding paths that made longevity work more legible or possible for others. The academic sources show research participation and one aging-biology workshop paper, but not field-creation activity attributable to him.
medium confidence
Bravery and conviction
0.0/ 10
The provided evidence contains no credible indication of public longevity-related risk-taking, contrarian advocacy, career sacrifice, sustained conviction under criticism, magnitude-of-bet, or self-experimentation. The dimension is applicable, but the evidence supports no bravery/conviction credit under the rubric.
medium confidence
Multiplier effect
2.0/ 10
The dimension applies, but the evidence shows only modest second-order leverage: Hanna appears in multi-institution scientific collaborations and a 2025 aging-biology workshop with other leading scientists. There is no evidence of founded organizations, investments, donations, policy influence, talent pipelines, public legitimacy campaigns, or follow-on projects beyond ordinary research collaboration.
low confidence
Vision
Destination
Hanna’s startup plans to use synthetic embryos as a kind of “bioprinter,” producing medically valuable cells in cases where other methods have failed.
There’s Renewal Bio, a startup Hanna cofounded, which hopes to grow synthetic embryos as a source of youthful replacement cells, such as bits of liver or even eggs.
His team is “trying to make entities at more advanced stages—depending on the goal, it could be day 30 in development, day 40, or day 70,” he told an audience last May in Cambridge, Massachusetts, where he’d traveled to join a panel discussion involving religious scholars and social scientists at the Global Observatory’s annual summit.
Renewal Bio, a Yeda spinoff company leveraging breakthrough stem cell technologies from Prof. Jacob Hanna's lab, to drive therapeutic advancements in genetic diseases, infertility, longevity and other disease areas.
Hanna imagines a cancer patient who needs a bone marrow transplant but can’t find a match. Could blood-forming cells be harvested from, say, 100 or 500 embryo-stage clones of that person, providing perfectly matched tissue?
Path
His research into stem cell-based models of early development is opening new frontiers for understanding how life builds itself—and how we might one day guide those processes in regenerative medicine.
His research into stem cell-based models of early development is opening new frontiers for understanding how life builds itself—and how we might one day guide those processes in regenerative medicine.
Scientists, including Hanna, are committed to refining their techniques to create even more faithful embryo models.
Check out in great detail how we derive Complete and Structured human day 14 post-implantation embryo models (SEMs) solely from unmodified naïve stem cells
Hanna’s startup plans to use synthetic embryos as a kind of “bioprinter,” producing medically valuable cells in cases where other methods have failed.
His company, Renewal, plans to use these synthetic embryos as a kind of “bioprinter,” producing medically valuable cells in cases where other methods have failed. This could be particularly valuable if the synthetic embryos are a perfect match with a patient’s DNA.
Strategy
Jacob Hanna's only supported longevity-relevant strategic focus is stem cell science; no investment, donation, founding, or collaboration strategy is evidenced.
The provided evidence supports a longevity-relevant focus on stem cell science through Hanna's self-description as a stem cell scientist [S1]. No investments, donations, founded organizations, or projects are evidenced, so there is no supported capital allocation or institution-building strategy [S1]. Stage preference, risk appetite, and time horizon are unknown from the available source [S1]. No collaborators, mentees, mentors, co-investors, or lineage links are supported by the evidence provided [S1].
UnknownUnknownStem Cell Science
Portfolio
Investments
No public rows yet.
Donations
No public rows yet.
Organizations founded
Scientific output
h-index29
Citations-
Papers7
Trials0
Bravery and conviction
Self-experimentation
Criticisms